Biotech Firm Faces Listing Requirement Challenge
Pomdoctor (NASDAQ: POM) confirmed receiving formal notification from Nasdaq regarding non-compliance with listing requirements. Market data shows the company’s American Depositary Shares (ADS) closed below the $1.00 minimum bid price threshold for 33 consecutive trading sessions.
Regulatory Requirements and Response Timeline
Under Nasdaq’s Marketplace Rules, listed securities must maintain a minimum closing bid price of $1 per share. The notification automatically triggers a 180-day cure period beginning from the notification date dated August 21, 2024.
Financial analysts note the company could regain compliance if its shares close at $1.00 or higher for at least ten consecutive business days during this period. Should Pomdoctor meet Nasdaq’s continued listing standards before the February 18, 2025 deadline, the matter would be resolved without further action.
Potential Extension and Contingency Plans
Market regulations permit a possible 180-day extension if the company demonstrates concrete plans to meet requirements through a reverse stock split or other corporate actions. Such measures would require shareholder approval and regulatory filings.
Pomdoctor maintains its listing remains active during the compliance period, with trading unaffected. The company stated it’s evaluating all options to address the deficiency while continuing normal business operations.
